Omnia Medical Reaches Settlement as PainTEQ Admits Breach and Patent Infringement
June 16, 2025, Morgantown, WV – After several years of litigation, Omnia and PainTEQ have fully and finally resolved all of the issues between them. As part of that resolution PainTEQ agreed to admit that it breached the parties’ Stocking Agreement, used Omnia’s PsiF trademark, and that PainTEQ’s Gen 2 cannula infringed Omnia’s D232 design patent. Omnia and PainTEQ agree that all of these issues have been corrected and they look forward to moving on with their respective businesses.
“The agreed upon settlement in this suit should bring some long overdue transparency and visibility to the pain space. A considerable amount of misinformation and confusion had been created, and this should bring clarity as to where the integrity stands. With as much scrutiny as interventional pain is facing, this will hopefully cause physicians to do a little more due diligence on the companies that they are being influenced to utilize.” – Troy Schifano, Omnia Medical CEO.
Omnia’s dispute with PainTEQ began in June 2020 when PainTEQ filed a lawsuit alleging business-related claims. In December 2020, Omnia responded with counterclaims including intellectual property infringement and contract-related issues. In January 2022, Omnia filed a separate case against PainTEQ and its owners, adding further patent and contract breach claims related to their prior distribution agreement. The cases were then consolidated in August 2023.
“Since the first PsiF procedure back in 2013 and our first peer-reviewed publication in November 2022, this settlement reaffirms Omnia as an innovator and leader in posterior SI joint arthrodesis. We continue to innovate today with our recent introduction of PsiF90, our PsiFGuard enabling technology, and our upcoming release of PsiF DNA. We remain committed to fair competition in the pain space and look forward to continuing to build on the clinical evidence that has been published utilizing the PsiF systems and instruments demonstrating the safety and effectiveness of our products.” – Chris Henneforth, Omnia Medical CFO.
For those interested in accessing more information about the above-referenced consolidated Federal Court Cases, including court details and case numbers, please visit https://www.flmd.uscourts.gov/pacer and reference US District Court – Middle District of Florida case number 8:20-cv-02805-VMC-AAS. If you are unable to access the filing, please email litigation@omniamedical.com.
For media inquiries, please contact:
Christopher Henneforth
